Skip to main content

Holiday schedule

Our Patient Service Centers will be closed on Wednesday, December 25, 2024 in observance of Christmas and Wednesday, January 1, 2025 in observance of New Year's Day. Have a healthy, happy holiday.

Hide
Quest Diagnostics

Insulin, Intact, LC/MS/MS

Test code(s) 93103

Insulin measurement is primarily used to evaluate the cause of hypoglycemia. Inappropriately elevated insulin in blood (hyperinsulinemia) is associated with hypoglycemia.1

Hyperinsulinemia can also be associated with disorders linked to hyperglycemia, such as metabolic syndrome.2 For assessment of hyperinsulinemia due to suspected insulin resistance, consider using CardioIQ® Insulin Resistance Panel with Score (test code 36509), which includes LC/MS/MS measurements of insulin, C-peptide, and calculated IR risk.

A limitation of most commercially available insulin assays is that they react not only with intact insulin, but also with fragments of the insulin molecule. This can lead to artificially high results. Quest Diagnostics offers the Insulin, Intact, LC/MS/MS (liquid chromatography-tandem mass spectrometry) assay (test code 93103), which measures only the intact insulin molecule.3 Insulin (test code 561) immunoassay can be used to evaluate the etiology of hypo- or hyperglycemia, but it is not equivalent to the LC/MS/MS test.

The assay includes high-throughput immunochemical enrichment of intact insulin from serum followed by liquid chromatography-tandem mass spectrometry (LC/MS/MS). Quantitation is based on standards traceable to the World Health Organization (WHO) international reference preparation 83/500.

Insulin testing may be considered in patients experiencing hypoglycemia of unknown cause, including seemingly healthy individuals without diabetes and individuals after bariatric surgery.

The analytical sensitivity is 3 µIU/mL and the analytical specificity provides no cross-reactivity with proinsulin nor insulin analogs aspart and degludec. Insulin analogs lispro and glargine may interfere with insulin quantitation. The presence of insulin antibodies may alter the test result. 

Elevated fasting insulin levels (>16 µU/mL) may be seen in patients with insulinoma, exogenous insulin, or type 2 diabetes mellitus (DM). Elevated insulin results could also be associated with a broad range of disorders including insulin resistance, obesity, hypertension, dyslipidemia, renal failure, atherosclerosis, sleep apnea, polycystic ovary syndrome, Cushing syndrome, noninsulinoma pancreatogenous hypoglycemia, acromegaly, Post-RYGB hypoglycemia and nesidioblastosis.4,5

For patients without known diabetes, a fasting insulin level >10 µU/mL is consistent with the presence of hepatic steatosis. For these patients, consider further evaluation to assess the presence and stage of nonalcoholic fatty liver disease (NAFLD).5

References

  1. Cryer PE, Axelrod L, Grossman AB, et al. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2009;94(3):709-728. doi:10.1210/jc.2008-1410
  2. Kelly CT, Mansoor J, Dohm GL, et al. Hyperinsulinemic syndrome: the metabolic syndrome is broader than you think. Surgery. 2014;156(2):405-411. doi:10.1016/j.surg.2014.04.028
  3. Taylor SW, Clarke NJ, Chen Z, et al. A high-throughput mass spectrometry assay to simultaneously measure intact insulin and C-peptide. Clin Chim Acta. 2016;455:202-208. doi:10.1016/j.cca.2016.01.019
  4. Resmini E, Minuto F, Colao A, et al. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities. Acta Diabetol. 2009;46:85-95. doi:10.1007/s00592-009-0112-9
  5. Bril F, McPhaul MJ, Kalavalapalli S, et al. Intact fasting insulin identifies nonalcoholic fatty liver disease in patients without diabetes. J Clin Endocrinol Metab. 2021;106(11):e4360-e4371. doi:10.1210/clinem/dgab417

 

This FAQ is provided for informational purposes only and is not intended as medical advice. Test selection and interpretation, diagnosis, and patient management decisions should be based on the clinician’s education, clinical expertise, and assessment of the patient.



Document FAQS.170 Version:1

Version 1: 06/02/2023 to present

Version 0: Effective 09/15/2015 to 06/02/2023

Related content

On-Demand Webinar
Detecting and Managing Insulin Resistance
Conference Presentation
Insulin resistance probability score and cardiovascular events in the elderly
Conference Presentation
Prevalence of High Insulin Resistance Probability Score in a Nation-Wide Working-Age Population
Test FAQ
NAFLD Fibrosis Score
Test FAQ
CardioIQ® Insulin Resistance Panel with Score
Publication
Intact Fasting Insulin Identifies Nonalcoholic Fatty Liver Disease in Patients Without Diabetes
Publication
An Insulin Resistance Score Improved Diabetes Risk Assessment in the Malmö Prevention Project-A Longitudinal Population-Based Study of Older European

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.